Several of these studies are designed to target RBM5, since deregulation of RBM5 and its downstream targets have been linked to tumorigenesis and tumor maintenance in a variety of cancers, including lung cancer, breast cancer, pancreatic cancer, prostate cancer, and vestibular schwannoma [3–8]. Here, RBM5 is linked to Familial prostate cancer.